The nature of early-stage endometrial cancer recurrence-A national cohort study

Eur J Cancer. 2016 Dec:69:51-60. doi: 10.1016/j.ejca.2016.09.033. Epub 2016 Nov 4.

Abstract

Background and aims: The aim of the study was to present a comprehensive analysis of disease recurrence in a large Danish cohort of women with early-stage endometrial cancer treated according to national guidelines.

Methods: All women diagnosed with stage I or II endometrial cancer in 2005-2009 were included in a population-based historical cohort derived from the Danish Gynaecological Cancer Database. Disease recurrence up to 3 years after the primary diagnosis was identified using national registers and hospital charts. Follow-up on survival ended on 31st December 2014. We evaluated the predictive value of clinico-pathological and sociodemographic variables using multivariate logistic regression.

Results: Recurrence within 3 years of the primary treatment was diagnosed in 183 (7%) of the included 2612 women. Site of recurrence significantly impacted on overall survival as the 5-year survival rate was 64.8% for women with vaginal recurrence and 17.5% in women with distant recurrence. Factors predictive of recurrence included the International Federation of Gynaecology and Obstetrics (FIGO) stage (OR: IB = 1.91, stage II = 3.91), Charlson comorbidity index of 3 (OR 1.86), non-endometrioid histology (OR 1.81) and being outside of the workforce (OR 1.81). Vaginal recurrence was predicted by FIGO stage only (OR: IB = 1.88, II = 2.79), while extra-vaginal recurrence was predicted by FIGO stage (OR: IB = 2.12, II = 3.31), Charlson comorbidity index of 3 (OR 1.88) and non-endometrioid histology (OR 2.51).

Conclusions: Future research should seek to understand the underlying mechanisms of the identified predictive factors to improve recurrence prediction and to reduce morbidity and mortality.

Keywords: Disease recurrence; Endometrial carcinoma; Gynaecological malignancy; RSS; Relapse; Risk stratification.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma, Clear Cell / epidemiology
  • Adenocarcinoma, Clear Cell / pathology
  • Adenocarcinoma, Clear Cell / therapy*
  • Age Factors
  • Aged
  • Body Mass Index
  • Carcinoma, Adenosquamous / epidemiology
  • Carcinoma, Adenosquamous / pathology
  • Carcinoma, Adenosquamous / therapy*
  • Carcinoma, Endometrioid / epidemiology
  • Carcinoma, Endometrioid / pathology
  • Carcinoma, Endometrioid / therapy*
  • Carcinosarcoma / epidemiology
  • Carcinosarcoma / pathology
  • Carcinosarcoma / therapy*
  • Chemoradiotherapy, Adjuvant
  • Chemotherapy, Adjuvant
  • Comorbidity
  • Denmark / epidemiology
  • Endometrial Neoplasms / therapy*
  • Female
  • Humans
  • Hysterectomy
  • Logistic Models
  • Lymph Node Excision
  • Lymph Nodes / pathology*
  • Middle Aged
  • Multivariate Analysis
  • Neoplasm Recurrence, Local / epidemiology*
  • Neoplasm Recurrence, Local / pathology
  • Neoplasm Staging
  • Neoplasms, Cystic, Mucinous, and Serous / epidemiology
  • Neoplasms, Cystic, Mucinous, and Serous / pathology
  • Neoplasms, Cystic, Mucinous, and Serous / therapy*
  • Ovariectomy
  • Pelvis
  • Radiotherapy, Adjuvant
  • Retirement / statistics & numerical data
  • Risk Factors
  • Salpingectomy
  • Sick Leave / statistics & numerical data
  • Smoking / epidemiology
  • Survival Rate
  • Time Factors
  • Unemployment / statistics & numerical data
  • Vagina / pathology